COMMUNIQUÉS West-GlobeNewswire

GHK-Cu Peptide Launched By Kylo Peptides for Laboratory Research Applications
17/08/2026
Sheridan,Wyoming, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com ] has added GHK-Cu peptide to its catalog of laboratory research materials, expanding the range of copper-binding compounds [...]
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
17/08/2026
Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; [...]
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES DU REGLEMENT-LIVRAISON DES TITRES EMIS DANS LE CADRE DE SON PLACEMENT PRIVE DE 14,2 MILLIONS D’EUROS ANNONCE LE 10 AOUT 2026 Paris, 17 août 2026, 7h30 AB Science S.A. ( [...]
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
17/08/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026 Paris, August 17, 2026, 7.30am CET AB Science S. [...]
Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down
17/08/2026
Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the [...]
Breast Augmentation in Dubai - Why Surgical Planning Matters More Than the Implant
17/08/2026
DUBAI, United Arab Emirates, Aug. 17, 2026 (GLOBE NEWSWIRE) -- With demand for aesthetic treatments continuing to rise across the UAE, women are increasingly seeking procedures of breast augmentation in Dubai that [...]
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
17/08/2026
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO ® as the backbone therapy across EGFRm lung cancer — HONG [...]
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
17/08/2026
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in [...]
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
14/08/2026
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion [...]
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
14/08/2026
WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported [...]
Precipio Announces Q2-2026 Financial Results
14/08/2026
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( [...]
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
14/08/2026
Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with [...]
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, [...]
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
14/08/2026
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, [...]
BioStem Technologies to Present at the Sidoti MicroCap Conference
14/08/2026
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/08/2026
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
4DMT Announces New Employment Inducement Grants
14/08/2026
EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
14/08/2026
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' [...]
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
14/08/2026
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics [...]

Pages